A Life-Course Approach to Vaccination Can Drive Healthy Aging

As life spans increase and birth-rates decrease, the world’s population is aging. From 2000 to 2025, the over-60 demographic segment will double from 600 million to almost 1.2 billion. By 2050, it will nearly double again, surpassing two billion and accounting for an incredible 22% of the total global population. A society this “old” has never before existed, and it is a social, ethical, and economic imperative to keep older adults healthy and engaged. It is timely for the global public health community to re-align its thinking, policies and activities to this new demographic reality.

Organizations at national and global levels have begun to pursue initiatives to promote healthy aging, and these efforts are going to intensify in the coming years. Thus far, the progress has been admirable, with the World Health Organization, the United Nations, the Organisation for Economic Co-operation and Development, and others taking leadership roles. Yet, despite many promising developments, the potential of “life-course immunization,” which stresses the administration of vaccines throughout all stages of life – including for adults – to prevent disease and promote health, has been largely overlooked, especially among adults.

Benefits of Immunizations in Adults

As adults age, they increase their risk of contracting vaccine-preventable diseases like pneumococcal disease, herpes zoster (shingles), and influenza, among others. Immunization in the adult years – and throughout the life-course – enables adults to age with reduced risk to such vaccine-preventable diseases. Disease-free, older adults can remain active, healthy participants in society while curtailing increases in healthcare expenses and more fully engaging in economic life.

  • Professor of Global Ageing, University of Stirling, Scotland
  • Marjorie Coote Professor of Health Care for Older People,
    University of Sheffield
  • Founder, Sheffield Institute for Studies on Ageing (Winner
    of 2000 Queen’s Anniversary Prize)

The on-line geriatric assessment can be combined with different courses. The price of the courses ranges from 40 CHF to 1000 CHF depending on the level of desired training. The progressive model with the digital assessment tool which Geneva-based company calls Respond 4.0 is supposed to reduce health costs. The papi-boomer phenomenon, coupled with medical care sometimes too prompt to hospitalize, costs a lot to public authorities, who pay more than half of the hospital bill.

There is a wealth of evidence to suggest the health and economic benefits of influenza vaccination in adult populations.”

—GCoA Founder Michael Hodin

Similar research could and should also be done for other vaccine-preventable diseases – like herpes zoster (shingles), influenza, and hepatitis B – that older adults run increased risk of contracting. As we discuss below, this should be a major policy priority for policymakers and other stakeholders. Furthermore, with this data supporting the public health benefits of various adult immunizations, new vaccine innovations would be incentivized and, eventually, brought to market. This is also how childhood immunizations were developed, and the model of success should be brought to innovations in adult vaccines.

Remaining Obstacles

For all of the potential of life-course immunization programs, there do remain a number of barriers to implementation. Research by the Alliance for Health and the Future shows that, globally, the causes for the lack of uptake of life-course vaccination programs include complex vaccination schedules and inadequate physician knowledge. Patients, too, have limited awareness of the benefits of vaccinations for themselves and their families. There is a lack of vaccination recommendation alignment among national and global bodies, and this, in part, prevents patients from complying with recommendations.

Part of the problem is ideological.  Embedded attitudes about vaccines would shift with increased understanding of their value as adult immunization becomes a central part of public health thinking. Throughout the industrialized world, it is common for people to get vaccines before they travel abroad in order to prevent disease, but they do not consider the disease risks they face while at home. In the developing world, there is often lack of awareness and resources. As we have seen over the past few decades with childhood vaccinations, access is only part of the equation. The other part is raising awareness and understanding of how vaccines can improve health. The GAVI Alliance has done a tremendous job of creating an appreciation for children’s vaccines in the developing world. A similar level of attention needs to be placed on the critical value of adult vaccines as the global population ages.

Policy Priorities to Promote Life-Course Immunization

A life-course approach to immunization can only become a reality for people around the world with the dedication of and coordinated follow-through by policymakers. The most essential first steps are:

  • Increase awareness regarding the health benefits of life-course immunization among health professionals, as well as employers, employee groups, and unions; to be led by local and national governments, as well as global organizations like the World Health Organization;
  • Establish or enhance existing surveillance systems to determine the burden of vaccine-preventable diseases in adults; to be accomplished through partnership between national and global bodies;
  • Create institutional alignment on adult vaccination schedules among leading organizations like the World Health Organization, the Centers for Disease Control and Prevention, the European Union, the Pan American Health Organization, and others willing to participate
  • Integrate adult immunizations into Personal Medical Records and create an adult immunization registry; to be accomplished through partnership between private and public organizations;
  • Integrate adult vaccination in public and private payer access programs;
  • Embed adult vaccination in core preventive services for adults; advocacy to be led by both public and private organizations with a stake in cost containment and improved health outcomes;
  • Bring adult immunization into global public health as a matter of course in our 21st century; led, for example, by the World Health Organization and other multi-governmental organizations and NGOs.

Over the last couple of years, health and aging experts have made significant strides in rolling out plans for healthy aging initiatives. From President Obama’s pledge to end Alzheimer’s by 2025 to the United Nations’ historic summit on non-communicable diseases, national and global health leaders have pioneered new paths for healthy aging. Conspicuously missing from these efforts is a campaign for life-course immunization. Policymakers around the world should put life-course immunization at the top of their agenda in order to enable healthy aging and support social and economic success in the 21st century.

Source: Health Affairs

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

Brazil Must Fight Antibiotic Resistance

The threat posed by antimicrobial resistance is urgent and spares no country - including Brazil. According to The Lancet, 63 deaths per 100,000 are associated with AMR in Brazil and Paraguay, a rate that exceeds the average for Latin America and the Caribbean. AMR-associated deaths in Brazil are second only to cardiovascular diseases and cancers.

We Missed 100 Million Adult Vaccines – Here’s How We Get Back on Track

Like other pandemics throughout human history, COVID-19 has caused profound changes that are still rippling through our societies, even as people are understandably eager to move on. In fact, these impacts are all the more dangerous when they are largely ignored or effectively invisible. The decline in adult vaccination may be one of the most significant, as a new report finds that ~100 million doses were missed in 2021 and 2022 alone – reversing global progress towards widespread adult immunisation as a new standard of care in a world of more old than young.

New Analysis Shows Lost Ground on Adult Immunisation During the Pandemic with 100 Million Doses Potentially Missed

New data shared today by GSK, in collaboration with the IQVIA Institute for Human Data Science and the Global Coalition on Aging (GCOA), estimate approximately 100 million fewer doses of some adult vaccines (excluding Covid-19 vaccines) were administered in 2021 and 2022 than anticipated, based on the global vaccination adoption trends observed from 2013 to 2020, compounding already low adoption rates pre-pandemic.

Going Beyond Applause: The Potential of Caregiving to Unlock Job Opportunities of the Future

Early in the COVID-19 pandemic, the role of caregivers – staff and family who provide care for older and dependent people to carry out activities such as eating or moving - catapulted to the front of our collective conscience. The daily applause for front-line care workers showed a high level of recognition for their incredible work and provided insight into how our health systems must change as our society ages. We need to continue to recognise caregivers as essential to our ageing society.

High-Level Forum on the Silver Economy 2023

Join us for the High-Level Forum on the Silver Economy 2023. Now in its fourth year, the Silver Economy Forum 2023, December 6 and 7, will explore aging at every stage of life, looking at the growing global Silver Economy through a multigenerational lens. Linking to the goals and aspirations of the UN Decade of Healthy Ageing, SEF 2023 will highlight key themes at the intersection of aging at every age, and the Silver Economy.

Global Coalition on Aging Workshop Calls on G7 Countries to Fund Pull Incentives to Spur Antibiotic Innovation

The Global Coalition on Aging, in partnership with JPMA, today announced the release of its workshop report on the AMR crisis facing G7 countries and the world, “The Value of Pull Incentives in Japan to Encourage Investment in Antibiotic Innovation to Solve the AMR Crisis.” If strong action is not taken to address AMR, we will lose the antibiotics we need to cure infections, which is likely to outpace cancer as a major cause of death, killing an estimated 10 million by 2050.